LinkedIn Profile

Access Pieris Pharmaceuticals historical Linkedin company profile data on number of followers, employee headcount and more

Rows

Open dataset
Ticker Symbol Entity Name As Of Date Company Name Followers Employees on Linkedin Link Industry Date Added Date Updated Description Website Specialities Logo HQ.Street HQ.City HQ.State HQ.Country HQ.Postal Headcount change in past 24 months Company Name Sector Industry
nasdaq:pirs 1419599 Apr 21st, 2024 12:00AM Pieris Pharmaceuticals 7.1K 67.00 Open Apr 20th, 2024 11:57PM Apr 20th, 2024 11:57PM Pieris is a biotechnology company based in Boston, Massachusetts that could potentially be entitled to receive development, regulatory, and sales-based milestones from its 4-1BB bispecifics immuno-oncology assets partnered with Pfizer (formerly Seagen), Boston Pharmaceuticals, and Servier. In addition to the milestone potential, Pieris would be eligible for sales royalties on the same partnered programs if they ultimately are approved for commercialization. The Company is seeking potential acquirers for its remaining preclinical and clinical assets. Pieris is listed on the NASDAQ and trades under the ticker symbol PIRS. For more information, visit www.pieris.com. Open IO Bispecific Open 225 Franklin Street Boston Massachusetts US 02110 Pieris Pharmaceuticals
nasdaq:pirs 1419599 Apr 20th, 2024 12:00AM Pieris Pharmaceuticals 7.1K 67.00 Open Apr 19th, 2024 11:54PM Apr 20th, 2024 05:29PM Pieris is a biotechnology company based in Boston, Massachusetts that could potentially be entitled to receive development, regulatory, and sales-based milestones from its 4-1BB bispecifics immuno-oncology assets partnered with Pfizer (formerly Seagen), Boston Pharmaceuticals, and Servier. In addition to the milestone potential, Pieris would be eligible for sales royalties on the same partnered programs if they ultimately are approved for commercialization. The Company is seeking potential acquirers for its remaining preclinical and clinical assets. Pieris is listed on the NASDAQ and trades under the ticker symbol PIRS. For more information, visit www.pieris.com. Open IO Bispecific Open 225 Franklin Street Boston Massachusetts US 02110 Pieris Pharmaceuticals
nasdaq:pirs 1419599 Apr 19th, 2024 12:00AM Pieris Pharmaceuticals 7.1K 67.00 Open Apr 19th, 2024 12:01AM Apr 19th, 2024 12:01AM Pieris is a biotechnology company based in Boston, Massachusetts that could potentially be entitled to receive development, regulatory, and sales-based milestones from its 4-1BB bispecifics immuno-oncology assets partnered with Pfizer (formerly Seagen), Boston Pharmaceuticals, and Servier. In addition to the milestone potential, Pieris would be eligible for sales royalties on the same partnered programs if they ultimately are approved for commercialization. The Company is seeking potential acquirers for its remaining preclinical and clinical assets. Pieris is listed on the NASDAQ and trades under the ticker symbol PIRS. For more information, visit www.pieris.com. Open IO Bispecific Open 225 Franklin Street Boston Massachusetts US 02110 Pieris Pharmaceuticals
nasdaq:pirs 1419599 Apr 18th, 2024 12:00AM Pieris Pharmaceuticals 7.1K 67.00 Open Apr 18th, 2024 12:20AM Apr 18th, 2024 06:49PM Pieris is a biotechnology company based in Boston, Massachusetts that could potentially be entitled to receive development, regulatory, and sales-based milestones from its 4-1BB bispecifics immuno-oncology assets partnered with Pfizer (formerly Seagen), Boston Pharmaceuticals, and Servier. In addition to the milestone potential, Pieris would be eligible for sales royalties on the same partnered programs if they ultimately are approved for commercialization. The Company is seeking potential acquirers for its remaining preclinical and clinical assets. Pieris is listed on the NASDAQ and trades under the ticker symbol PIRS. For more information, visit www.pieris.com. Open IO Bispecific Open 225 Franklin Street Boston Massachusetts US 02110 Pieris Pharmaceuticals
nasdaq:pirs 1419599 Apr 17th, 2024 12:00AM Pieris Pharmaceuticals 7.1K 67.00 Open Apr 16th, 2024 11:52PM Apr 17th, 2024 03:15PM Pieris is a biotechnology company based in Boston, Massachusetts that could potentially be entitled to receive development, regulatory, and sales-based milestones from its 4-1BB bispecifics immuno-oncology assets partnered with Pfizer (formerly Seagen), Boston Pharmaceuticals, and Servier. In addition to the milestone potential, Pieris would be eligible for sales royalties on the same partnered programs if they ultimately are approved for commercialization. The Company is seeking potential acquirers for its remaining preclinical and clinical assets. Pieris is listed on the NASDAQ and trades under the ticker symbol PIRS. For more information, visit www.pieris.com. Open IO Bispecific Open 225 Franklin Street Boston Massachusetts US 02110 Pieris Pharmaceuticals
nasdaq:pirs 1419599 Apr 16th, 2024 12:00AM Pieris Pharmaceuticals 7.1K 66.00 Open Apr 15th, 2024 11:49PM Apr 16th, 2024 11:31AM Pieris is a biotechnology company based in Boston, Massachusetts that could potentially be entitled to receive development, regulatory, and sales-based milestones from its 4-1BB bispecifics immuno-oncology assets partnered with Pfizer (formerly Seagen), Boston Pharmaceuticals, and Servier. In addition to the milestone potential, Pieris would be eligible for sales royalties on the same partnered programs if they ultimately are approved for commercialization. The Company is seeking potential acquirers for its remaining preclinical and clinical assets. Pieris is listed on the NASDAQ and trades under the ticker symbol PIRS. For more information, visit www.pieris.com. Open IO Bispecific Open 225 Franklin Street Boston Massachusetts US 02110 Pieris Pharmaceuticals
nasdaq:pirs 1419599 Apr 15th, 2024 12:00AM Pieris Pharmaceuticals 7.1K 66.00 Open Apr 14th, 2024 11:43PM Apr 15th, 2024 05:13PM Pieris is a biotechnology company based in Boston, Massachusetts that could potentially be entitled to receive development, regulatory, and sales-based milestones from its 4-1BB bispecifics immuno-oncology assets partnered with Pfizer (formerly Seagen), Boston Pharmaceuticals, and Servier. In addition to the milestone potential, Pieris would be eligible for sales royalties on the same partnered programs if they ultimately are approved for commercialization. The Company is seeking potential acquirers for its remaining preclinical and clinical assets. Pieris is listed on the NASDAQ and trades under the ticker symbol PIRS. For more information, visit www.pieris.com. Open IO Bispecific Open 225 Franklin Street Boston Massachusetts US 02110 Pieris Pharmaceuticals
nasdaq:pirs 1419599 Apr 14th, 2024 12:00AM Pieris Pharmaceuticals 7.0K 66.00 Open Apr 13th, 2024 11:32PM Apr 13th, 2024 11:32PM Pieris is a biotechnology company based in Boston, Massachusetts that could potentially be entitled to receive development, regulatory, and sales-based milestones from its 4-1BB bispecifics immuno-oncology assets partnered with Pfizer (formerly Seagen), Boston Pharmaceuticals, and Servier. In addition to the milestone potential, Pieris would be eligible for sales royalties on the same partnered programs if they ultimately are approved for commercialization. The Company is seeking potential acquirers for its remaining preclinical and clinical assets. Pieris is listed on the NASDAQ and trades under the ticker symbol PIRS. For more information, visit www.pieris.com. Open IO Bispecific Open 225 Franklin Street Boston Massachusetts US 02110 Pieris Pharmaceuticals
nasdaq:pirs 1419599 Apr 13th, 2024 12:00AM Pieris Pharmaceuticals 7.0K 66.00 Open Apr 12th, 2024 11:24PM Apr 13th, 2024 11:58AM Pieris is a biotechnology company based in Boston, Massachusetts that could potentially be entitled to receive development, regulatory, and sales-based milestones from its 4-1BB bispecifics immuno-oncology assets partnered with Pfizer (formerly Seagen), Boston Pharmaceuticals, and Servier. In addition to the milestone potential, Pieris would be eligible for sales royalties on the same partnered programs if they ultimately are approved for commercialization. The Company is seeking potential acquirers for its remaining preclinical and clinical assets. Pieris is listed on the NASDAQ and trades under the ticker symbol PIRS. For more information, visit www.pieris.com. Open IO Bispecific Open 225 Franklin Street Boston Massachusetts US 02110 Pieris Pharmaceuticals
nasdaq:pirs 1419599 Apr 12th, 2024 12:00AM Pieris Pharmaceuticals 7.0K 66.00 Open Apr 11th, 2024 11:30PM Apr 12th, 2024 08:53AM Pieris is a biotechnology company based in Boston, Massachusetts that could potentially be entitled to receive development, regulatory, and sales-based milestones from its 4-1BB bispecifics immuno-oncology assets partnered with Pfizer (formerly Seagen), Boston Pharmaceuticals, and Servier. In addition to the milestone potential, Pieris would be eligible for sales royalties on the same partnered programs if they ultimately are approved for commercialization. The Company is seeking potential acquirers for its remaining preclinical and clinical assets. Pieris is listed on the NASDAQ and trades under the ticker symbol PIRS. For more information, visit www.pieris.com. Open IO Bispecific Open 225 Franklin Street Boston Massachusetts US 02110 Pieris Pharmaceuticals

Request a demo to view additional historical data, and much more.

Request Demo

Make fast
queries

No longer rely on engineers to access data; build and share queries with intuitive tools, and derive insights in real time.

Bookmark queries with your team

Save and share custom queries using a private bookmarking feature, accessible to your whole team.

Be first to know with alerts

Scan data points across millions of companies and receive emails when relevant metrics cross critical thresholds.

Visualize data for quick insights

Create custom keyword-based word clouds, charts, and advanced visualizations to quickly analyze the data.

Map competitor locations

Analyze competitor presence and growth over time by overlaying store locations with the Nearby Competitor feature.

Add widgets to your dashboards

Access existing maps, charts, word clouds, and other visualizations to understand your data quickly. Or build custom widgets to view data just the way you want it.